Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acrivon Therapeutics, Inc.’s SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on precision oncology. Its 8-K reports cover results of operations, financial condition, Regulation FD presentations, pipeline updates for ACR-368 and ACR-2316, and disclosures related to its internal CLIA-certified laboratory and companion diagnostic activities.
The company’s proxy materials describe annual meeting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. Filing records also identify the company’s common stock registration on Nasdaq and provide exhibits that support business updates, clinical program presentations, material agreements, and risk-related public-company reporting.
Acrivon Therapeutics, Inc. Chief Operating Officer Eric Devroe reported an open-market purchase of company stock. On 01/13/2026, he bought 10,000 shares of Acrivon common stock at a weighted average price of $1.7218 per share, executed in multiple trades within a price range of $1.719 to $1.7268. Following this purchase, he beneficially owns 75,308 shares of Acrivon common stock in direct ownership.
Acrivon Therapeutics, Inc. reported that it hosted a corporate webcast and conference call on January 8, 2026, featuring a presentation by its leadership team and an interactive Q&A session. In connection with this event, the company posted a presentation on its investor relations website titled the January 8, 2026 Data Update. This presentation includes clinical data and program updates for the ACR-368 program as well as initial clinical data for ACR-2316.
The same January 8, 2026 Data Update has been furnished as Exhibit 99.1 to this report under a Regulation FD disclosure item, and is expressly not deemed filed for liability purposes under the Exchange Act unless later specifically incorporated by reference.
Acrivon Therapeutics reported preliminary unaudited cash, cash equivalents and investments of about $119 million as of December 31, 2025, which it currently expects will fund operations into the second quarter of 2027. This extends its financial runway as it advances multiple oncology programs.
The company highlighted updated Phase 2b data for ACR-368 in endometrial cancer, with an overall response rate of 39% in one trial arm and higher confirmed response rates in serous endometrial cancer, guiding a focus on this subgroup and expansion of Arm 3 into the EU with up to 90 subjects. Initial Phase 1 results for ACR-2316 showed tolerability and tumor shrinkage, including a confirmed partial response in endometrial cancer and unconfirmed responses in small cell and squamous non-small cell lung cancers.
Acrivon also nominated ACR-6840, a CDK11 inhibitor, as its next development candidate and outlined milestones through 2026, including Phase 2 updates and Phase 3 readiness for ACR-368, further ACR-2316 data and dose expansion, an IND submission for ACR-6840, and additional AP3-driven programs.
Acrivon Therapeutics, Inc. insiders report routine share withholding for taxes. President and CEO Dr. Peter Blume-Jensen reported that on 11/21/2025, 19,904 shares of common stock were disposed of at $2.30 per share, identified as shares withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units. Following this transaction, he beneficially owned 2,046,771 shares directly and 314,706 shares indirectly.
The indirect holdings reflect spousal ownership between co-founders Dr. Blume-Jensen and EVP – Business Operations Dr. Kristina Masson. Each spouse disclaims beneficial ownership of the other's securities except to the extent of their pecuniary interest, which clarifies how their combined economic exposure to Acrivon’s stock is reported.
Acrivon Therapeutics, Inc. (ACRV) reported an administrative insider transaction by its Chief Accounting Officer. On 11/14/2025, 99 shares of common stock were withheld by the company at a price of $2.24 per share to cover mandatory tax withholding upon the vesting of restricted stock units. After this tax-related share withholding, the officer beneficially owned 4,122 shares of Acrivon common stock directly.
Acrivon Therapeutics, Inc. reported an insider equity transaction involving its Chief Legal Officer. On 11/14/2025, 184 shares of common stock were disposed of at a price of $2.24 per share. The filing explains that these shares were withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units, rather than being sold in an open-market transaction.
After this tax withholding event, the reporting officer beneficially owns 34,555 shares of Acrivon Therapeutics common stock, held directly. The Form 4 is filed by a single reporting person and reflects routine equity compensation administration for the officer role.
Acrivon Therapeutics, Inc. reported an insider equity transaction by its Chief Development Officer. On 11/14/2025, 403 shares of Acrivon Therapeutics common stock were disposed of at a price of $2.24 per share. The filing explains that these shares were withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units, rather than being an open-market sale. Following this withholding event, the officer beneficially owned 15,283 shares of Acrivon Therapeutics common stock, held directly.
Acrivon Therapeutics, Inc. reported a routine insider equity transaction by its Chief Operating Officer. On 11/14/2025, 613 shares of Acrivon common stock were withheld at a price of $2.24 per share to cover mandatory tax withholding when restricted stock units vested. After this tax-related withholding, the officer beneficially owns 65,308 shares of Acrivon common stock in direct ownership. The filing is administrative in nature and reflects standard equity compensation and tax settlement practices for a senior executive.
Acrivon Therapeutics, Inc. insiders reported routine tax‑related share transactions. On 11/14/2025, President and CEO Dr. Peter Blume-Jensen had 59,765 shares of common stock withheld by the company at $2.24 per share to cover mandatory tax withholding upon vesting of restricted stock units, leaving him with 2,066,675 shares held directly. On the same date, 490 shares were similarly withheld at $2.24 per share from holdings reported as indirect, leaving 314,706 shares held indirectly. The filing notes that Dr. Blume-Jensen and co-founder and EVP – Business Operations Dr. Kristina Masson are spouses and each disclaims beneficial ownership of the other’s securities except to the extent of their pecuniary interest.
Acrivon Therapeutics (ACRV) reported Q3 2025 results, highlighting continued investment in its precision oncology programs. The company posted a net loss of $18.2 million for the quarter, improving from $22.4 million a year ago, as research and development expense decreased to $13.6 million (from $18.9 million). General and administrative expense was $6.0 million. Basic and diluted net loss per share was $0.47.
For the nine months ended September 30, net loss was $58.9 million, with operating cash use of $48.4 million. Acrivon ended the quarter with cash, cash equivalents and investments of $134.4 million, which management states is sufficient for at least 12 months and supports a projected runway into the second quarter of 2027.
Pipeline progress continued. The registrational‑intent Phase 2 trial of ACR‑368 in endometrial cancer previously reported a 35% confirmed ORR and 80% tumor shrinkage in OncoSignature‑positive patients. The ACR‑368 OncoSignature test has FDA Breakthrough Device designation, and ACR‑368 holds Fast Track status. ACR‑2316, a WEE1/PKMYT1 inhibitor, is in Phase 1 with initial signs of activity, including a confirmed partial response at dose level 3. As of November 7, 2025, shares outstanding were 31,555,126.